Comparison
Magnesium L-Threonate vs Metformin
Magnesium L-Threonate
MIT-developed magnesium that crosses the blood-brain barrier. Shown to enhance synaptic density and reduce 'brain age'.
Metformin
Anti-diabetic medication studied for longevity. AMPK activator. Glucose normalization.
| Field | Magnesium L-Threonate | Metformin |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–2000mg | 500–2000mg |
| Half-life | 6h | — |
| Onset | — | — |
| Evidence | EVIDENCEB | EVIDENCEA |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USRx |
| PubMed refs | 90 | 23000 |
The comparison in plain English
Auto-generated from dataMagnesium L-Threonate and Metformin are both in the neuroprotective category respectively. Magnesium L-Threonate MIT-developed magnesium that crosses the blood-brain barrier. Metformin Anti-diabetic medication studied for longevity.
Bottom line
Magnesium L-Threonate (evidence B, safety 5/5) has a stronger evidence base than Metformin (evidence A, safety 4/5). Magnesium L-Threonate has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Magnesium L-Threonate if
Magnesium L-Threonate is the better fit when your goal aligns with its mechanism (L-threonate is a sugar-acid carrier that uniquely enables magnesium to cross the blood-brain barrier in meaningful quantities — most oral magnesium forms (oxide, citrate, glycinate) raise serum magnesium but not central magnesium) and the dose range (1000–2000mg) suits your protocol. Half-life is 6h.
Choose Metformin if
Metformin is the better fit when your goal aligns with its mechanism (Activates AMP-activated protein kinase (AMPK), the cellular energy sensor that mimics caloric restriction signalling) and the dose range (500–2000mg) suits your protocol. Half-life is —h.